Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin added to loop diuretics in type 2 diabetes with chronic heart failure
2016-003968-39Phase 4Completed
- Sponsor
- University of Dundee
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and chronic heart failure (CHF) comparing Jardiance plus loop diuretic with Placebo plus loop diuretic (2 arms). Primary endpoint: Change in urinary volume. Started May 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2016-003968-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003968-39.